Paclitaxel-Induced Lung Injury and Its Amelioration by Parecoxib Sodium
Researchers investigated the mechanism of paclitaxel-induced lung injury and its amelioration by parecoxib sodium. They observed changes in alveolar ventilation function, alveolar-capillary membrane permeability, lung tissue pathology and measured the levels of inflammatory cytokines and cyclooxygenase-2 in lung tissue, the expression of tight junction proteins. [Sci Rep] Full Article
Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Clovis Oncology Enters into Clinical Trial Collaboration
Clovis Oncology, Inc. announced that they have entered into a clinical trial collaboration with Genentech to evaluate a novel combination therapy of Genentech’s investigational cancer immunotherapy atezolizumab and rociletinib for the treatment of advanced EGFR-mutant non-small cell lung cancer. [Clovis Oncology, Inc.] Press Release
DefiniGEN Licenses Lung Stem Cell Technology from University of Cambridge
DefiniGEN Ltd. announced that it has strengthened its IP portfolio with a license for cutting edge lung stem cell technology from the University of Cambridge. The technology will be used by DefiniGEN to develop new, optimized cell products and services for drug discovery and the study of lung diseases, including cystic fibrosis. [DefiniGEN Ltd.] Press Release